Fig. 3. Reduced aPKC activity results in increased cell death in PAR6N cells. (A) aPKC activity and PAR6 expression levels were analyzed in wild-type MDCK and PAR6N cells by immunoblot using, respectively, phospho-aPKC, total-aPKC and PAR6B antibodies. The quantification of three independent experiments is depicted. ^*P<0.05. (B) MDCK cysts grown in collagen were treated with either the non-myristoylated (control) or myristoylated form of aPKC pseudosubstrate peptide, at the indicated concentrations, at day 4; aPKC pseudosubstrate-containing media were refreshed at day 6. Immunostaining with Ki-67 (green) and cleaved caspase-3 (red) were performed at day 7. Bar, 10 µm. (C) Percentage of cysts containing apoptotic cells was quantified by cleaved caspase-3 staining comparing control and aPKC inhibitor-treated cells. Results are the mean±s.d. of three experiments.